FDA and FTC Issue Warning Letters to Three CBD Companies
The ambiguities surrounding the use and distribution of CBD products is intense. While several bills on CBD and Hemp move through the Florida Legislature to seek clarification and establish requirements in Florida, yesterday the FDA issued a statement announcing new steps and actions it is taking on the lawful marketing of appropriate cannabis and cannabis-derived products.
Much of the FDA and FTC concerns involve the product developers’ false misrepresentations and unproven claims that the CBD products will treat serious or life-threatening diseases and mislead patients. It is also the false advertisements that CBD is a hemp supplement or dietary supplement that is concerning to the FDA.
The FDA and FTC issued warning letters to three companies, warning of the consequences of false advertisements: Advanced Spine and Pain, LLC (d/b/a Relievus) out of Mount Laurel, NJ ; Nutra Pure, LLC out of Vancouver, WA, and PotNetwork Holdings, Inc., out of Fort Lauderdale, Florida.
The FCA will continue to keep you apprised of legislative actions on CBD / Hemp.
To see the full April 2, 2019, FDA Statement, click here.